Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival. | Int J Mol Sci | 2024 | 38999968 | PubTator, text mining | PubMed |
| The complex association between the immune system and the skeletal system in osteoporosis: A study of single-cell RNA sequencing. | Int Immunopharmacol | 2024 | 38976947 | PubTator, text mining | PubMed |
| Augmenting CAR T-cell Functions with LIGHT. | Cancer Immunol Res | 2024 | 38959337 | PubTator, text mining | PubMed |
| Multilayered Computational Framework for Designing Peptide Inhibitors of HVEM-LIGHT Interaction. | J Phys Chem B | 2024 | 38958133 | PubTator, text mining | PubMed |
| Causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomisation study. | J Cancer | 2024 | 38947379 | PubTator, text mining | PubMed |
Primary pulmonary epithelioid hemangioendothelioma metastatic to the pleura and mediastinal lymph node with a prominent rhabdoid cytomorphology showing CAMTA1::WWTR1 fusion and novel PRDM1 and TNFRSF14 mutations. | Cytopathology | 2024 | 38943251 | PubTator, text mining | PubMed |
| Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. | Oncoimmunology | 2024 | 38939518 | PubTator, text mining | PubMed |
| Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer. | Vaccines (Basel) | 2024 | 38932345 | PubTator, text mining | PubMed |
| Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution. | Diagn Pathol | 2024 | 38909266 | PubTator, text mining | PubMed |
| Genetically predicted N-methylhydroxyproline levels mediate the association between naive CD8+ T cells and allergic rhinitis: a mediation Mendelian randomization study. | Front Immunol | 2024 | 38846949 | PubTator, text mining | PubMed |
| Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer. | Transl Oncol | 2024 | 38838438 | PubTator, text mining | PubMed |
| The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients. | Front Immunol | 2024 | 38835768 | PubTator, text mining | PubMed |
| The BTLA-HVEM axis restricts CAR T cell efficacy in cancer. | Nat Immunol | 2024 | 38831106 | PubTator, text mining | PubMed |
| HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function. | Cell Oncol (Dordr) | 2024 | 38809326 | PubTator, text mining | PubMed |
| Deciphering the circulating immunological landscape of thoracic aortic aneurysm: Insights from a two-sample Mendelian randomization study. | Heliyon | 2024 | 38803862 | PubTator, text mining | PubMed |
| An Aging-Related lncRNA Signature Establishing for Breast Cancer Prognosis and Immunotherapy Responsiveness Prediction. | Pharmgenomics Pers Med | 2024 | 38803444 | PubTator, text mining | PubMed |
| Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia. | Biomolecules | 2024 | 38785930 | PubTator, text mining | PubMed |
| lncRNA CDKN2B-AS1 is downregulated in patients with ventricular fibrillation in acute myocardial infarction. | PLoS One | 2024 | 38771854 | PubTator, text mining | PubMed |
| Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma. | Mod Pathol | 2024 | 38763418 | PubTator, text mining | PubMed |
| Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma. | Biomed Pharmacother | 2024 | 38733770 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=11